Alnylam Pharmaceuticals Inc (ALNY)vsMoonLake Immunotherapeutics (MLTX)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
MLTX
MoonLake Immunotherapeutics
$18.02
+7.84%
HEALTHCARE · Cap: $1.21B
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
MLTX
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for MLTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
No standout strengths identified
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : MLTX
MLTX has a balanced fundamental profile.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : MLTX
The primary concerns for MLTX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while MLTX is a value play — different risk/reward profiles.
MLTX carries more volatility with a beta of 1.24 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 26/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
MoonLake Immunotherapeutics
HEALTHCARE · BIOTECHNOLOGY · USA
MoonLake Immunotherapeutics is a pioneering biotechnology company focused on developing innovative therapies for chronic inflammatory diseases using its proprietary drug delivery platform. The firm is currently advancing its lead product candidate, a novel interleukin-17 inhibitor, through clinical trials, aiming to provide transformative treatment solutions that could significantly enhance patient outcomes. With a strong research pipeline and strategic partnerships, MoonLake is well-positioned to impact the immunotherapy market, addressing critical unmet medical needs while creating substantial value for shareholders.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?